Sun Pharma Sees Profit Jump 26% Driven by India and Specialty Drugs

Sun Pharmaceutical Industries reported a strong fourth quarter for FY26, with net profit rising 26.2% from the previous year to ₹2,714 crore. The company's revenue increased by 12.8% to ₹14,611 crore, benefiting from a focus on specialty products and expansion in key markets.

Growth Drivers Highlighted

Sun Pharma's performance in India was a key factor, with its formulations business growing 14.8% and capturing a market share of 8.4%. This represents significant market share gains since the Ranbaxy acquisition. In the United States, the Innovative Medicines business crossed the $1 billion revenue mark for the full fiscal year 2026. While overall US formulation sales saw a slight 1.1% decrease, the growth in innovative medicines is significantly boosting the company's margins.

Financial Overview and Strategy

For the full fiscal year 2025-26, Sun Pharma's net profit increased by 5% to ₹11,479 crore, and revenue grew 11.9% to ₹58,220 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose 16.1% to ₹17,731 crore, with EBITDA margins improving to 30.3% for the year. The company is also integrating its recent $11.75 billion acquisition of Organon, aiming to strengthen its position as a global pharmaceutical leader. Research and development investments for FY26 were ₹35,540 million, equal to 6.1% of total sales.

Shareholder Returns and Valuation

Sun Pharma's current price-to-earnings (P/E) ratio is around 41.03, indicating investor confidence in its growth and stability. The board proposed a final dividend of ₹5 per equity share for FY26, making the total annual dividend ₹16 per share. This payout is consistent with the previous fiscal year and reflects the company's strong liquidity and cash flow.

Potential Challenges

Despite the positive results, Sun Pharma faces some challenges. The slight decline in US formulation sales points to ongoing pricing pressures and potential regulatory issues in the generics market. The integration of the large Organon acquisition carries inherent risks, and its success will be crucial for realizing projected synergies and future growth. The company's valuation, while reflecting growth expectations, also means it could be vulnerable to market downturns if growth slows or integration proves difficult. Sun Pharma's market capitalization was approximately ₹4.52 trillion in May 2026.